Synthaverse Past Earnings Performance
Past criteria checks 1/6
Synthaverse has been growing earnings at an average annual rate of 70.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 10.5% per year. Synthaverse's return on equity is 4.2%, and it has net margins of 8.1%.
Key information
70.8%
Earnings growth rate
70.9%
EPS growth rate
Biotechs Industry Growth | 56.3% |
Revenue growth rate | 10.5% |
Return on equity | 4.2% |
Net Margin | 8.1% |
Next Earnings Update | 22 May 2024 |
Recent past performance updates
Recent updates
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking
Apr 20Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems
Apr 18BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly
Oct 14More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%
Nov 29We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings
Nov 16Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?
May 02Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?
Mar 08What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?
Jan 29Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jan 03BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt
Dec 07Revenue & Expenses BreakdownBeta
How Synthaverse makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 59 | 5 | 25 | 0 |
30 Sep 23 | 53 | 3 | 22 | 0 |
30 Jun 23 | 58 | 7 | 20 | 0 |
31 Mar 23 | 54 | 7 | 18 | 0 |
31 Dec 22 | 50 | 6 | 17 | 0 |
30 Sep 22 | 51 | 7 | 17 | 0 |
30 Jun 22 | 44 | 4 | 16 | 0 |
31 Mar 22 | 44 | 5 | 15 | 0 |
31 Dec 21 | 41 | 4 | 15 | 0 |
30 Sep 21 | 39 | 5 | 15 | 0 |
30 Jun 21 | 40 | 5 | 15 | 0 |
31 Mar 21 | 35 | 2 | 16 | 0 |
31 Dec 20 | 40 | 4 | 16 | 0 |
30 Sep 20 | 41 | 2 | 15 | 0 |
30 Jun 20 | 40 | 3 | 15 | 0 |
31 Mar 20 | 40 | 3 | 15 | 0 |
31 Dec 19 | 39 | 2 | 15 | 0 |
30 Sep 19 | 35 | -29 | 16 | 0 |
30 Jun 19 | 36 | -31 | 17 | 0 |
31 Mar 19 | 35 | -32 | 17 | 0 |
31 Dec 18 | 32 | -32 | 16 | 0 |
30 Sep 18 | 31 | 10 | 15 | 0 |
30 Jun 18 | 31 | 11 | 16 | 0 |
31 Mar 18 | 30 | 1 | 17 | 0 |
31 Dec 17 | 31 | 1 | 18 | 0 |
30 Sep 17 | 31 | -23 | 18 | 0 |
30 Jun 17 | 32 | -27 | 20 | 0 |
31 Mar 17 | 37 | -26 | 20 | 0 |
31 Dec 16 | 36 | -26 | 20 | 0 |
30 Sep 16 | 46 | -48 | 21 | 0 |
30 Jun 16 | 45 | -45 | 18 | 0 |
31 Mar 16 | 47 | -35 | 18 | 0 |
31 Dec 15 | 43 | -37 | 17 | 0 |
30 Sep 15 | 38 | -2 | 14 | 0 |
30 Jun 15 | 36 | -2 | 13 | 0 |
31 Mar 15 | 31 | -2 | 12 | 0 |
31 Dec 14 | 34 | 0 | 12 | 0 |
30 Sep 14 | 28 | -3 | 11 | 0 |
30 Jun 14 | 29 | 0 | 12 | 0 |
31 Mar 14 | 31 | 0 | 13 | 0 |
31 Dec 13 | 33 | 1 | 14 | 0 |
30 Sep 13 | 32 | -2 | 16 | 0 |
30 Jun 13 | 26 | -5 | 16 | 0 |
Quality Earnings: SVE has a high level of non-cash earnings.
Growing Profit Margin: SVE's current net profit margins (8.1%) are lower than last year (12.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SVE has become profitable over the past 5 years, growing earnings by 70.8% per year.
Accelerating Growth: SVE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SVE had negative earnings growth (-21.8%) over the past year, making it difficult to compare to the Biotechs industry average (-11.5%).
Return on Equity
High ROE: SVE's Return on Equity (4.2%) is considered low.